Bio-Path Holdings (BPTH) - Long-Term Debt to Capital

Bio-Path Holdings (BPTH) is establishing a biochemical environment for RNA-based treatment of blood pathologies, while market price action reflects the 0.00 indicator. Drug development is constrained by strict regulatory oversight and the need for capital to complete testing. The company is currently focusing on creating unique therapy methods, remaining in the pre-revenue stage and competing with peers for priority in clinical trials.

This metric is calculated as the ratio of liabilities with a maturity of more than one year to equity. It determines the extent of the company's reliance on long-term debt financing relative to its net assets. For Bio-Path Holdings (BPTH), which lacks revenue and depends on equity offerings, the debt load is secondary compared to share dilution. By analyzing the long-term liabilities-to-equity ratio, an investor assesses the stability of the balance sheet structure. A downward trend in the curve confirms a reduction in debt pressure.